Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and admin

Change in fair value of acquisition consideration

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Twist Bioscience Corp

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. Its products include genes, oligo pools, Next Generation Sequencing (NGS), variant libraries, synthetic controls, antibody discovery, and SARS-CoV-2 Tools. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Twist Bioscience Corp meets Q1 expectations, eyes growth opportunities

Twist Bioscience Corp's Q1 performance met or exceeded expectations across key revenue segments, with a focus on expanding customer base and improving turnaround times.
While facing challenges such as COVID impact on China sales and margin dips due to fixed costs, the company aims for revenue growth and improved margins through strategic execution.
The company's strengths lie in strong gross margins, record bookings in NGS, and efforts towards DNA data storage alliances, positioning for future growth and innovation.
Opportunities include continued customer expansion, Fast Gene market development, and revenue growth driven by NGS and SynBio performance, amidst a value-based pricing strategy.

Twist Bioscience Corp achieves $60.2M revenue in Q2 2023

Twist Bioscience Corp's Q2 2023 earnings call highlighted strong revenue growth, cost reduction efforts, and a focus on achieving profitability. The company is navigating challenges in the biopharma sector while leveraging strengths in technology and sales execution for future growth.

Twist Bioscience Corp reports record Q3 revenue, focuses on growth

Twist Bioscience Corp delivered a strong performance in Q3, with record revenue and strategic product launches driving growth across key segments.
While facing challenges in biopharma revenue and commercial execution, the company is focused on expansion, talent acquisition, and cost management to drive future growth.
With a clear focus on innovation, market expansion, and achieving profitability milestones, Twist Bioscience Corp is well-positioned for future success and market leadership.
The company's strengths in SynBio products, strategic market positioning, and stable funding outlook underscore its potential for sustained growth and value creation.

Twist Bioscience Corp reports robust revenue growth and eyes profitability

Twist Bioscience Corp's Q4 2023 earnings call highlighted strong revenue growth, operational efficiency, and a solid financial position.
The company faces challenges in managing expenses and achieving profitability but sees opportunities in revenue growth and market expansion.
By leveraging strengths in product launches, customer relationships, and revenue growth, Twist Bioscience aims for continued success and margin expansion in fiscal 2024.

Twist Bioscience Corp excels in Q1 2024, focuses on growth

Twist Bioscience Corp's Q1 2024 earnings call highlighted robust revenue growth, margin expansion, and strategic focus on operational efficiency. The company's emphasis on customer needs, premium pricing, and cost efficiency positions it well for future growth and profitability.

Twist Bioscience reports robust Q2 revenue growth and margin targets

Twist Bioscience Corp delivered strong revenue growth and aims for margin improvement, driven by successful product lines and strategic initiatives.
While facing challenges in managing expenses and achieving profitability, the company is well-positioned to leverage market opportunities and regulatory advantages.
With a focus on innovation, market expansion, and margin growth, Twist is poised for continued success and competitive growth in the biopharma sector.
Navigating operational challenges and seizing growth opportunities will be crucial for Twist Bioscience to achieve its financial targets and sustain market leadership.

Twist Bioscience Corp reports robust Q3 revenue growth and profitability outlook

Twist Bioscience Corp delivered strong revenue growth and operational performance in Q3 2024, driven by robust NGS and biopharma revenue streams.
While facing challenges in achieving profitability targets, the company's focus on margin improvement and capacity expansion positions it for future growth.
Guidance for fiscal 2024 indicates promising revenue growth, highlighting opportunities for sustained expansion and enhanced financial performance.

Twist Bioscience Corp reports record revenue and aims for profitability

Twist Bioscience Corp delivered strong financial performance, with record revenue and margin growth driven by key product segments and operational efficiencies.
The company's focus on achieving adjusted EBITDA profitability and cash flow positivity, along with robust fiscal 2025 guidance, signals a path towards sustainable growth.
While challenges like cost management and market competition persist, opportunities in market traction, revenue diversification, and innovation position the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

ChargePoint Holdings

Lemonade

Nano Dimension

Palantir Technologies

Sunrun

Tecnoglass

While 2023 was the year of the Magnificent Seven, the seven outperforming stocks in this article are likely to be winners that will surge past the broader indices, such as the S&P 500 and the Nasdaq. The reason is that these companies trade at low valuations and have robust outlooks for this year and beyond.

7 Sexy Stocks That Will Continue to Outperform in 2024

Twist Bioscience reported strong results in the first quarter of FY2024, despite a tepid demand environment. Growth was somewhat exaggerated by lumpy NGS revenue, but overall the business is progressing well, particularly from a profitability perspective. Twist's share price has increased significantly in recent months, which probably means that near-term upside is limited.

Twist Bioscience: Strong Performance In A Soft Market

SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element's AVITI™ System. “Element continues to expand its customer.

Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today launched the cfDNA Library Preparation Kit to enable liquid biopsy research. Liquid biopsies have gained prominence in critical applications such as cancer screening, including multi-cancer early detection screening and monitoring for minimal residual disease (MRD). Liquid biopsy te.

Twist Bioscience Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced technology early access of the Twist Flex Prep Ultra High-Throughput (UHT) Kit, which aims to enable unparalleled throughput at a fraction of the cost of existing on market solutions, accelerating NGS' microarray conversion and adoption in agricultural genomics. Built upon.

Twist Bioscience Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT

Twist Bioscience Corporation (TWST) Q1 2024 Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2024 ended December 31, 2023. "We're starting fiscal 2024 off strong with record revenue of $71.5 million for the first fiscal quarter, coming in above our projection, with a gross margin of 40.5%," s.

Twist Bioscience Reports Fiscal First Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of Twist Express Genes, a new leading gene synthesis service with an order to shipping turnaround starting at five business days1, to include larger DNA preparations up to 1 milligram. The Express Genes offering, initially launched in November 2023, now exten.

Twist Bioscience Expands Express Genes Rapid Synthesis Service

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 first quarter ended December 31, 2023, before the opening of the market on Friday, February 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. East.

Twist Bioscience to Report Fiscal 2024 First Quarter Financial Results on Friday, February 2, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 50,000 restricted stock units (“RSUs”) and 70,000 shares subject to the Company's executive compensation programs to Adam Laponis, Twist's recently appointed chie.

Twist Bioscience Corporation Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Adam Laponis as chief financial officer. Mr. Laponis brings experience across small cap and Fortune 50 companies along with a track record of collaborating across teams to drive profitable growth. “Adam's deep financial acumen and strategic planning expe.

Twist Bioscience Appoints Adam Laponis as Chief Financial Officer

CRISPR Therapeutics

Recursion Pharmaceuticals

Genomics is undeniably medicine's future, and genomics stocks stand to be the next big thing in healthcare as the industry matures. But the crux of the matter is when the industry will mature.

3 Genomics Stocks to Unlock the Future of Medicine

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 5:15 p.m. Pacific Time in San Francisco, CA. The presentation will be webcast live and can be accessed by visiti.

Twist Bioscience to Present at 42nd Annual J.P. Morgan Healthcare Conference

Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Twist Bioscience (TWST) Soars 12.5%: Is Further Upside Left in the Stock?

Amazon

ARK Innovation ETF

Coinbase

Microsoft

NVIDIA

Roku

Block

ARK Innovation ETF (ARKK), which provides thematic multi-cap exposure to innovation across sectors, has gained 35.2%, becoming the best-performing ETF of November.

5 Best Performing Stocks of the Top ETF of November

Twist Bioscience Corporation (NASDAQ:TWST ) Q4 2023 Results Conference Call November 17, 2023 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs and Chief ESG Officer Dr. Emily Leproust - CEO and Co-Founder Jim Thorburn - Acting CFO Conference Call Participants Luke Sergott - Barclays Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Puneet Souda - Leerink Partners Catherine Schulte - Baird Steven Mah - TD Cowen Sung-Ji Nam - Scotiabank Madeline Mollman - William Blair Operator Welcome to the Twist Bioscience's Fiscal 2023 Fourth Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Twist Bioscience Corporation (TWST) Q4 2023 Earnings Call Transcript

Twist Bioscience beat quarterly expectations Friday and guided to "solid" sales growth for the upcoming year, leading TWST stock to rocket.

DNA-Maker Twist Bioscience Catapults 21% As 'Solid' Outlook That Tops Its Peers

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the fourth quarter and full year fiscal 2023 ended September 30, 2023. “Fiscal 2023 was a defining year for Twist as we grew our revenue 20% year over year with strength in NGS and synbio in particular,” said Emily M. Leproust,.

Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2023 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Express Genes, a new leading gene synthesis service with an order to shipping turnaround time of five to seven business days.1 “Twist Express Genes is our first new offering enabled by the increased capacity and streamlined processes in our Wilsonville.

Twist Bioscience Launches Express Genes Rapid Gene Synthesis Service

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28 at 7:30 a.m. Eastern Time in Miami, FL. The fi.

Twist Bioscience to Present at 6th Annual Evercore ISI HealthCONx Conference

Today, we take a look synthetic biology company Twist Bioscience Corporation for the first time since spring. The company recently signed collaboration deals with two new drugmakers and saw upward analyst price target revisions after strong Q2 results.

A New Look At Twist Bioscience

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 fourth quarter and full year ended September 30, 2023, before the opening of the market on Friday, November 17, 2023. The company plans to hold a conference call and live audio webcast for analysts and investors.

Twist Bioscience to Report Fiscal 2023 Fourth Quarter and Full Year Financial Results on Friday, November 17, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Full Length Unique Dual Index Adapters to enable PCR-free whole genome sequencing (WGS) and multiplexing at scale. The new adapters include unique dual indexing (UDI) sequences, along with flow cell binding site and sequencing priming site, enabling NGS.

Twist Bioscience Launches Full Length Unique Dual Index Adapters to Enable PCR-free Whole Genome Sequencing

Bayer AG

BERLIN--(BUSINESS WIRE)--Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform. The company's “Library of Libraries,” a collection of synthetic antibody libraries that harnesses innovative structural and developability features to cover a wide range of antibody drug targets, is tailored to address specific challenges in antibody discovery. It has the potential to.

Bayer to Partner With Twist Bioscience to Accelerate Drug Discovery

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an antibody discovery, option and license agreement with Bayer. Under the terms of the agreement, Twist Biopharma Solutions, a division of Twist Bioscience, will leverage its Library of Libraries to conduct antibody discovery campaigns against targets to be determined by B.

News for Twist Bioscience Corp Stock (TWST)